Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma

Saad Z. Usmani, MD
Published: Monday, Jun 19, 2017



Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

CAR T-cell therapies have been making their way through the field of multiple myeloma. Studies presented at the 2017 ASCO Annual Meeting showed that when targeting BCMA, CAR T-cell technology appeared to be tolerable and efficacious, Usmani says.

Larger cohorts are needed though, Usmani adds, as investigators still must indicate which patients will benefit from this therapy.
 
SELECTED
LANGUAGE


Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

CAR T-cell therapies have been making their way through the field of multiple myeloma. Studies presented at the 2017 ASCO Annual Meeting showed that when targeting BCMA, CAR T-cell technology appeared to be tolerable and efficacious, Usmani says.

Larger cohorts are needed though, Usmani adds, as investigators still must indicate which patients will benefit from this therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x